User:Mr. Ibrahem/Futibatinib

Futibatinib, sold under the brand name Lytgobi, is a medication used to treat bile duct cancer (cholangiocarcinoma). Specifically it is used for cases that cannot be removed by surgery, are fibroblast growth factor receptor 2 (FGFR2) gene fusion positive, and have failed other treatment. It is taken by mouth.

Common side effects include nail problems, muscle pain, constipation, diarrhea, tiredness, dry mouth, hair loss, kidney problems, liver problems, low platelets, low white blood cells, electrolyte problems, and urinary tract infection. Other side effects may include eye problems (retinal detachment) and soft tissue mineralization. Use in pregnancy may harm the baby. It is a kinase inhibitor, specifically a FGFR1-4 inhibitor.

Futibatinib was approved for medical use in the United States in 2022. While an application for approved has been submitted in Europe it is not approved their as of 2022. The potential cost in the United States is unclear as of October 2022.